Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG, a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Healthy Humans
Sponsor: CellSight Technologies, Inc.
This PHASE1 trial investigates Cancer and is currently completed. CellSight Technologies, Inc. leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CellSight Technologies, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .